Evidence map›Paper›PMID 39779582›Full record

ArticleAAPS PharmSciTech2025

Inclusion Complex of Nimodipine with Sulfobutylether-β-cyclodextrin: Preparation, Characterization, In Vitro and In Vivo Evaluation.

Jiahui Liu, Meichai Li, Yongjie Huang, Xinyu Wang, Youfa Xu, Zhiqin Fu, Zhizhe Lin, Jianming Chen, Xin Wu

Abstract read
PubMed Publisher
In one paragraph

Article in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jiahui LiuDepartment of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, 350108, China.
Meichai LiDepartment of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, 350108, China.
Yongjie HuangDepartment of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, 350108, China.
Xinyu WangShanghai Wei Er Lab, Shanghai, China.
Youfa XuShanghai Wei Er Lab, Shanghai, China.
Zhiqin FuShanghai Wei Er Lab, Shanghai, China.
Zhizhe LinShanghai Wei Er Lab, Shanghai, China.
Jianming ChenDepartment of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, 350108, China. chenjm0711@163.com.
Xin WuDepartment of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, 350108, China. wuxin007@126.com.ORCID http://orcid.org/0000-0003-2875-355X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nimodipine (NIMO) is used to treat ischemic nerve injury from subarachnoid hemorrhage (SAH), but its low aqueous solubility limits clinical safety and bioavailability. This study aims to improve NIMO's solubility by preparing inclusion complexes with sulfobutylether-β-cyclodextrin (SBE-β-CD), reducing the limitations of Nimotop

Indexed as

beta-CyclodextrinsNimodipineSolubilityAnimalsBiological AvailabilityChemistry, PharmaceuticalDrug StabilityHemolysisMaleMiceRatsRats, Sprague-DawleySpectroscopy, Fourier Transform Infraredbeta-CyclodextrinsNimodipineSBE4-beta-cyclodextrinbiosafetyinclusion complexintracerebral hemorrhageNIMO-CDnimodipinesulfobutylether-β-cyclodextrin

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.